JP7195252B2 - 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 - Google Patents

特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 Download PDF

Info

Publication number
JP7195252B2
JP7195252B2 JP2019522657A JP2019522657A JP7195252B2 JP 7195252 B2 JP7195252 B2 JP 7195252B2 JP 2019522657 A JP2019522657 A JP 2019522657A JP 2019522657 A JP2019522657 A JP 2019522657A JP 7195252 B2 JP7195252 B2 JP 7195252B2
Authority
JP
Japan
Prior art keywords
cancer
ctc
ctcs
cdna
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501517A5 (https=
JP2020501517A (ja
Inventor
ハーバー，ダニエル・エイ
マヘスワラン，シャマラ
トドロバ，ターニャ
カリニチ，マーク
ミヤモト，デイビッド・トモアキ
ホン，シン
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2020501517A publication Critical patent/JP2020501517A/ja
Publication of JP2020501517A5 publication Critical patent/JP2020501517A5/ja
Priority to JP2022142901A priority Critical patent/JP7441907B2/ja
Application granted granted Critical
Publication of JP7195252B2 publication Critical patent/JP7195252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
JP2019522657A 2016-10-27 2017-10-27 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析 Active JP7195252B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022142901A JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413952P 2016-10-27 2016-10-27
US62/413,952 2016-10-27
PCT/US2017/058855 WO2018081625A2 (en) 2016-10-27 2017-10-27 Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022142901A Division JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Publications (3)

Publication Number Publication Date
JP2020501517A JP2020501517A (ja) 2020-01-23
JP2020501517A5 JP2020501517A5 (https=) 2020-12-03
JP7195252B2 true JP7195252B2 (ja) 2022-12-23

Family

ID=62025512

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522657A Active JP7195252B2 (ja) 2016-10-27 2017-10-27 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
JP2022142901A Active JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022142901A Active JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Country Status (5)

Country Link
US (2) US11371101B2 (https=)
EP (2) EP3532642B1 (https=)
JP (2) JP7195252B2 (https=)
CN (1) CN110050075B (https=)
WO (1) WO2018081625A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016238253B2 (en) 2015-03-25 2022-06-16 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
CN110050075B (zh) * 2016-10-27 2024-04-02 通用医疗公司 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
WO2020006098A2 (en) * 2018-06-26 2020-01-02 Children's National Medical Center Tumor-associated markers for detection of minimal residual disease using digital droplet pcr
WO2020102506A1 (en) * 2018-11-14 2020-05-22 The Broad Institute, Inc. Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法
JP2022547735A (ja) * 2019-09-16 2022-11-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 乳房がんの分子特徴付けに基づく処置の方法
JP7534426B2 (ja) * 2020-09-09 2024-08-14 株式会社日立ハイテク 代謝物パネルによるがん検査法
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
US20240159632A1 (en) * 2021-03-16 2024-05-16 Sony Group Corporation Closed-system automated sample sorting system
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
JP2024527371A (ja) * 2021-07-08 2024-07-24 オウロテック インコーポレイテッド 処置の有効性予測システム及び方法
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用
WO2025259592A1 (en) * 2024-06-10 2025-12-18 Genecentric Therapeutics, Inc. Therapeutic predictive response signatures and uses thereof in cancer patients

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512510A (ja) 2001-05-16 2005-05-12 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として乳癌で発現される遺伝子
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
US20150168413A1 (en) 2012-07-02 2015-06-18 The General Hospital Corporation Diagnosis and monitoring treatment of prostrate cancer
US20150240314A1 (en) 2012-09-14 2015-08-27 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
WO2016145308A2 (en) 2015-03-12 2016-09-15 Janssen Pharmaceutica Nv Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
WO2016154600A1 (en) 2015-03-25 2016-09-29 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
US8535A (en) 1851-11-18 Stove-geate
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
CA2652052A1 (en) 2006-05-16 2007-11-29 Nugen Technologies, Inc. Nucleic acid separation and purification method based on reversible charge interactions
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US9625454B2 (en) 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
US20110166030A1 (en) 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
US20120329061A1 (en) 2010-03-11 2012-12-27 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
AU2015268617A1 (en) * 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
ES2525382T3 (es) * 2010-03-31 2014-12-23 Sividon Diagnostics Gmbh Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
US9650629B2 (en) 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
WO2012135397A2 (en) * 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
GB2510539B (en) 2011-10-24 2016-04-20 Gen Hospital Corp Biomarkers of cancer
AU2013302867A1 (en) 2012-08-13 2015-02-26 The Regents Of The University Of California Methods and systems for detecting biological components
US9671405B2 (en) * 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
US20140154681A1 (en) * 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
WO2014165762A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
EP3058316B1 (en) 2013-10-18 2019-03-13 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
CA2941161A1 (en) * 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
MA40271A (fr) * 2014-05-21 2017-03-29 Hoffmann La Roche Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
DK3230736T3 (da) * 2014-12-12 2020-06-08 Celcuity Inc Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
EP3259375B1 (en) 2015-02-20 2019-01-09 Comelz S.p.a. Method for cutting natural hides
CN110050075B (zh) * 2016-10-27 2024-04-02 通用医疗公司 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512510A (ja) 2001-05-16 2005-05-12 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として乳癌で発現される遺伝子
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
US20150168413A1 (en) 2012-07-02 2015-06-18 The General Hospital Corporation Diagnosis and monitoring treatment of prostrate cancer
US20150240314A1 (en) 2012-09-14 2015-08-27 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
WO2016145308A2 (en) 2015-03-12 2016-09-15 Janssen Pharmaceutica Nv Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
WO2016154600A1 (en) 2015-03-25 2016-09-29 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples

Also Published As

Publication number Publication date
WO2018081625A2 (en) 2018-05-03
EP3985127A1 (en) 2022-04-20
EP3532642B1 (en) 2021-12-08
JP2022184902A (ja) 2022-12-13
US20220364185A1 (en) 2022-11-17
US11371101B2 (en) 2022-06-28
CN110050075A (zh) 2019-07-23
WO2018081625A3 (en) 2018-06-07
EP3532642A2 (en) 2019-09-04
US12331363B2 (en) 2025-06-17
EP3532642A4 (en) 2020-06-24
CN110050075B (zh) 2024-04-02
JP2020501517A (ja) 2020-01-23
JP7441907B2 (ja) 2024-03-01
US20190391134A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JP7441907B2 (ja) 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
US11898209B2 (en) Digital analysis of circulating tumor cells in blood samples
Alunni-Fabbroni et al. Circulating tumour cells in clinical practice: Methods of detection and possible characterization
WO2014160120A1 (en) Compositions and methods for detecting and determining a prognosis for prostate cancer
CN106795557A (zh) 用于肺癌诊断的方法和系统
Görner et al. Genetic analysis of circulating tumor cells in pancreatic cancer patients: A pilot study
CN110747275B (zh) 肿瘤细胞标记分子及其应用
Lianidou et al. Development and validation of molecular assays for liquid biopsy applications
CA2980562C (en) Digital analysis of circulating tumor cells in blood samples
Zainfeld et al. Liquid Biopsy: Translating Minimally Invasive Disease Profiling from the Lab to the Clinic
Škereňová Individualization of the treatment of prostate cancer patients based on the immunocytochemical detection of circulating tumor cells
HK1249553B (en) Digital analysis of circulating tumor cells in blood samples
Jojo Optimization of Circulating Tumor Cells Isolation for Gene Expression Analysis
HK1238306A1 (en) Method and systems for lung cancer diagnosis
HK1213297B (zh) 用於檢測和測定前列腺癌預後的組合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220908

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220929

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221213

R150 Certificate of patent or registration of utility model

Ref document number: 7195252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250